Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of LT3001 in Participants With Acute Ischemic Stroke (AIS)

NCT07754825 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT07754825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07754825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of LT3001 in Participants With Acute Ischemic Stroke (AIS)
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke